Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 107, Issue 8, Pages 975-984Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI11273
Keywords
-
Categories
Funding
- NHLBI NIH HHS [P01 HL046345, HL-46345, HL-62845] Funding Source: Medline
- NIGMS NIH HHS [R01 GM020069, GM-20069, F31 GM020069] Funding Source: Medline
Ask authors/readers for more resources
Mice lacking natriuretic peptide receptor A (NPRA) have marked cardiac hypertrophy and chamber dilatation disproportionate to their increased blood pressure (BP), suggesting, in support of previous in vitro data, that the NPRA system moderates the cardiac response to hypertrophic stimuli. Here, we have followed the changes in cardiac function in response to altered mechanical load on the heart of NPRA-null mice (Npr1(-/-)). Chronic treatment with either enalapril, furosemide, hydralazine, or losartan were all effective in reducing and maintaining BP at normal levels without affecting heart weight/body weight. In the reverse direction, we used transverse aortic constriction (TAC) to induce pressure overload. In the Npr1(-/-) mice, TAC resulted in a 15-fold increase in atrial natriuretic peptide (ANP) expression, a 55% increase in left ventricular weight/body weight (LV/BW), dilatation of the LV, and significant decline in cardiac function. In contrast, banded Npr1(+/+) mice showed only a threefold increase in ANP expression, an 11% increase in LV/BW, a 0.2 mm decrease in LV end diastolic dimension, and no change in fractional shortening. The activation of mitogen-activated protein kinases that occurs in response to TAC did not differ in the Npr1(+/+) and Npr1(-/-) mice. Taken together, these results suggest that the NPRA system has direct antihypertrophic actions in the heart, independent of its role in BP control.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available